Journal of Antivirals & Antiretrovirals
Open Access

Abstract

Boceprevir and Calcineurin Inhibitors – is there a Role for Treating Hepatitis C Recurrence after Liver Transplantation?

Sandeep Mukherjee

Cirrhosis from Hepatitis C (HCV) remains the leading indication for liver transplantation in the United States with recurrent disease leading to cirrhosis in 42% of patients by 5 years post-transplant. Aspegylated interferon (PIF) and ribavirin (RBV) are only effective in approximately 30% of patients with recurrent HCV genotype 1, this has led to recurrent HCV emerging as an important but controversial indication for retransplantation. On the other hand, the approval of protease inhibitors (PI’s) for the treatment of pre-transplant patients with HCV genotype 1 in 2011 has rapidly transformed our management of this ubiquitous disease.